API

Active Pharmaceutical Ingredients (API), popularly speaking, are the raw materials of medicines, only pharmaceutical raw materials are processed into pharmaceutical preparations , can they become medicines available for clinical use, so drugs we usually eat are the finished drugs through processing. Active Pharmaceutical Ingredients based on its sources can be divided into two major categories ,including chemical synthetic drugs and natural chemical drugs. Chemical synthetic drugs can be divided into organic synthetic drugs and inorganic synthetic drugs. Inorganic synthetic drugs are inorganic compounds ( very few is element), such as aluminum hydroxide, magnesium trisilicate which are used for the treatment of gastric and duodenal ulcers ; organic synthetic drugs are mainly composed of drugs made by basic organic chemical raw materials, through a series of organic chemical reactions (such as aspirin, chloramphenicol, caffeine, etc.). Natural chemical drugs ,based on its sources,can be divided into two categories including biochemical drugs and plant chemical drugs. Antibiotics are generally made by the microbial fermentation, which belongs to the biochemistry category. A variety of semi-synthetic antibiotics occurs in recent years,which are biosynthesis and chemical synthesis combining products.Among active Pharmaceutical Ingredients, the organic synthetic drugs varieties, yields and values have the largest proportion,which are the main pillars of the chemical and pharmaceutical industries. The quality of active Pharmaceutical Ingredients decides whether the formulation is good or bad , so its quality standards are very strict ,countries in the world have developed national pharmacopoeia standards and strict quality control methods for its widely used active Pharmaceutical ingredients.

The Role of Dolutegravir Sodium in Transforming HIV Care: From Mechanism of Action to Clinical Application

Dolutegravir sodium is a potent antiretroviral medication primarily used in the treatment of human immunodeficiency virus (HIV) infection.

Apr 8,2024  API

Beryllium Diboride: Crystal Structure

It was shown that Beryllium Diboride has four stable crystal structures, cubic (space group , NO.216), orthorhombic (space group Pnma, NO.62), orthorhombic (space group Pbam, NO.55 ) and hexagonal (sp

Apr 3,2024  API

Dabrafenib Mesylate(GSK-2118436B): Pharmacodynamics and Applications in Cancer

Dabrafenib Mesylate(GSK-2118436B) targets BRAF V600E in cancer, synergizing with trametinib to inhibit the RAS/RAF/MEK/ERK pathway, showing efficacy in various cancers.

Apr 3,2024  API

Polyquaternium-10: Properties, Applications in Skincare and Detection Method

Polyquaternium-10, derived from hydroxyethyl cellulose, offers conditioning benefits in skincare and haircare, with a novel detection method ensuring accurate levels in cosmetic products.

Apr 3,2024  API

EUROPIUM(II) SELENIDE: Crystal Structure

EUROPIUM(II) SELENIDE consists of the elemental system Eu-Se forming black (or brown) cubic conjugated crystals with the space group Fm3m, cell parameter a = 0.6185 nm and Z = 4.

Apr 2,2024  API

Q:When was sorafenib tosylate approved by the FDA?

A:On December 20, 2005, the Food and Drug Administration (FDA) granted regular marketing approval for sorafenib tosylate 200-mg tablets.

Apr 2,2024  API

What is the side effect of Nintedanib (BIBF-1120)

Nintedanib (BIBF-1120) is an orally administered intracellular tyrosine kinase inhibitor (TKI) initially developed as an antitumor agent.

Apr 2,2024  API

Dasatinib monohydrate: Structure and Synthesis method

Dasatinib monohydrate is a potent, orally active, multitargeted inhibitor of several critical oncogenic kinases which was developed by Bristol-Myers Squibb.

Apr 2,2024  API

Bromodiphenylmethane: Overview, Applications in Synthesis of N-Substituted Benzamides and Preparation

Bromodiphenylmethane enables N-substituted benzamide synthesis for pain treatment, showcasing its value and potential in pharmaceutical research and industrial applications.

Apr 2,2024  API

The brief introduction of Sorafenib

Sorafenib is a multikinase inhibitor that has recently obtained Food and Drug Administration (FDA) approval for the treatment of advanced renal cell carcinoma (RCC).

Apr 1,2024  API
Prev12345678910...Next>  Go to Page